Literature DB >> 2418307

Clonidine prevents the sympathetic initiation and aggravation of poststenotic myocardial ischemia.

G Heusch, J Schipke, V Thämer.   

Abstract

We studied the effects of clonidine (10 micrograms/kg i.v.) on the positive feedback between poststenotic myocardial ischemia and cardiac sympathetic nerve activation and on the initiation of poststenotic myocardial ischemia during bilateral carotid occlusion in 12 anesthetized, open-chest dogs. During 20 min of acute severe coronary stenosis, cardiac sympathetic nerve activity increased by 24 +/- 6%, poststenotic coronary resistance increased from 0.45 +/- 0.05 to 0.61 +/- 0.08 mm Hg . min . 100 g/ml, and the poststenotic myocardial lactate consumption of 25 +/- 6 mumol/min . 100 g at 1 min of stenosis was reversed to a net lactate production of 8 +/- 3 mumol/min . 100 g after 20 min of stenosis. An additional 60-s bilateral carotid occlusion increased cardiac sympathetic nerve activity furthermore to 157 +/- 7% of control, increased poststenotic coronary resistance to 0.84 +/- 0.14 mm Hg . min . 100 g/ml, and increased the net lactate production to 22 +/- 6 mumol/min . 100 g. With heart rate and left ventricular pressure kept constant, clonidine decreased cardiac sympathetic nerve activity to 21 +/- 6% of control and prevented any further sympathetic activation during 20 min of coronary stenosis and bilateral carotid occlusion. Conversely, poststenotic coronary resistance and myocardial lactate consumption remained unchanged. Intracoronary clonidine (100 micrograms) in five of the 12 dogs increased poststenotic coronary resistance from 0.47 +/- 0.04 to 0.61 +/- 0.05 mm Hg . min . 100 g/ml and reversed the myocardial lactate consumption of 36 +/- 4 mumol/min . 100 g to a net lactate production of 7 +/- 5 mumol/min . 100 g. Our results suggest that clonidine can, by a central nervous action, prevent the sympathetic initiation and aggravation of poststenotic myocardial ischemia and may thus be effective in the treatment of exertional angina.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2418307     DOI: 10.1097/00005344-198511000-00026

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Dexmedetomidine: a novel sedative-analgesic agent.

Authors:  R Gertler; H C Brown; D H Mitchell; E N Silvius
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

2.  Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery?

Authors:  J Boldt; G Rothe; E Schindler; C Döll; G Görlach; G Hempelmann
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

Review 3.  Pharmacological mechanisms to attenuate sympathetically induced myocardial ischemia.

Authors:  R Schulz; B D Guth; G Heusch
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

4.  Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?

Authors:  D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin
Journal:  Rom J Anaesth Intensive Care       Date:  2021-01-04

5.  Central Sympathetic Activation and Arrhythmogenesis during Acute Myocardial Infarction: Modulating Effects of Endothelin-B Receptors.

Authors:  Theofilos M Kolettis; Marianthi Kontonika; Eleonora Barka; Evangelos P Daskalopoulos; Giannis G Baltogiannis; Christos Tourmousoglou; Apostolos Papalois; Zenon S Kyriakides
Journal:  Front Cardiovasc Med       Date:  2015-02-23

6.  Dexmedetomidine attenuates hypoxia/reoxygenation injury in primary neonatal rat cardiomyocytes.

Authors:  Ke Peng; Yun Qiu; Jian Li; Zhao-Cai Zhang; Fu-Hai Ji
Journal:  Exp Ther Med       Date:  2017-06-01       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.